Ultra High-Risk Myeloma

被引：57

作者：

Avet-Loiseau, Herve ^{[1
]}

机构：

[1] Inst Biol, Lab Hematol, F-44093 Nantes 09, France

来源：

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2010年

关键词：

STEM-CELL TRANSPLANTATION; LENALIDOMIDE PLUS DEXAMETHASONE; MULTIPLE-MYELOMA; INTERGROUPE-FRANCOPHONE; ELDERLY-PATIENTS; STAGING SYSTEM; SURVIVAL; BORTEZOMIB; THERAPY; THALIDOMIDE;

D O I：

10.1182/asheducation-2010.1.489

中图分类号：

G40 [教育学];

学科分类号：

040101 ; 120403 ;

摘要：

Ultra high-risk myeloma can be defined as myeloma leading to death within 24 months. Despite tremendous improvements in the past decade (especially because of the availability of novel drugs such as thalidomide, bortezomib, and lenalidomide), these patients still represent 15% to 20% of the patients. Many prognostic factors can help to define these patients, including age, renal insufficiency, poor performance status, comorbities, International Staging System (ISS) stage 3, high proliferation, leukemic presentation, and acquired genetic changes, as defined by interphase fluorescence in situ hybridization or genomics. Several combinations of these prognostic parameters can define ultra high-risk patients, making a universal therapeutic proposal almost impossible. However, focusing on fit patients with ISS 3, high proliferation, and poor-risk genetic changes, these patients should probably benefit from dose-dense and prolonged therapeutic schemas, ideally within prospective trials.

引用

页码：489 / 493

页数：5

共 37 条

[1] Single versus double autologous stem-cell transplantation for multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Facon, T ;

Guilhot, F ;

Doyen, C ;

Fuzibet, JG ;

Monconduit, M ;

Hulin, C ;

Caillot, D ;

Bouabdallah, R ;

Voillat, L ;

Sotto, JJ ;

Grosbois, B ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2495-2502

[2] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Stoppa, AM ;

Sotto, JJ ;

Fuzibet, JG ;

Rossi, JF ;

Casassus, P ;

Maisonneuve, H ;

Facon, T ;

Ifrah, N ;

Payen, C ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97

[3] Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma [J].

Attal, Michel ;

Harousseau, Jean-Luc ;

Leyvraz, Serge ;

Doyen, Chantal ;

Hulin, Cyrille ;

Benboubker, Lofti ;

Agha, Ibrahim Yakoub ;

Bourhis, Jean-Henri ;

Garderet, Laurent ;

Pegourie, Brigitte ;

Dumontet, Charles ;

Renaud, Marc ;

Voillat, Laurent ;

Berthou, Christian ;

Marit, Gerald ;

Monconduit, Mathieu ;

Caillot, Denis ;

Grobois, Bernard ;

Avet-Loiseau, Herve ;

Moreau, Philippe ;

Facon, Thierry .

BLOOD, 2006, 108 (10) :3289-3294

[4] Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma [J].

Avet-Loiseau, H. ;

Moreau, P. ;

Mathiot, C. ;

Charbonnel, C. ;

Facon, T. ;

Attai, M. ;

Hulin, C. ;

Marit, G. ;

Minvielle, S. ;

Harousseau, J. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[5] Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia:: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique [J].

Avet-Loiseau, H ;

Daviet, A ;

Brigaudeau, C ;

Callet-Bauchu, E ;

Terré, C ;

Lafage-Pochitaloff, M ;

Désangles, F ;

Ramond, S ;

Talmant, P ;

Bataille, R .

BLOOD, 2001, 97 (03) :822-825

[6] Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome [J].

Avet-Loiseau, Herve ;

Attal, Michel ;

Moreau, Philippe ;

Charbonnel, Catherine ;

Garban, Frederic ;

Hulin, Cyrille ;

Leyvraz, Serge ;

Michallet, Mauricette ;

Yakoub-Agha, Ibrahim ;

Garderet, Laurent ;

Marit, Gerald ;

Michaux, Lucienne ;

Voillat, Laurent ;

Renaud, Marc ;

Grosbois, Bernard ;

Guillerm, Gaelle ;

Benboubker, Lotfi ;

Monconduit, Mathieu ;

Thieblemont, Catherine ;

Casassus, Philippe ;

Caillot, Denis ;

Stoppa, Anne-Marie ;

Sotto, Jean-Jacques ;

Wetterwald, Marc ;

Dumontet, Charles ;

Fuzibet, Jean-Gabriel ;

Azais, Isabelle ;

Dorvaux, Veronique ;

Zandecki, Marc ;

Bataille, Regis ;

Minvielle, Stephane ;

Harousseau, Jean-Luc ;

Facon, Thierry ;

Mathiot, Claire .

BLOOD, 2007, 109 (08) :3489-3495

[7] Prognostic Significance of Copy-Number Alterations in Multiple Myeloma [J].

Avet-Loiseau, Herve ;

Li, Cheng ;

Magrangeas, Florence ;

Gouraud, Wilfried ;

Charbonnel, Catherine ;

Harousseau, Jean-Luc ;

Attal, Michel ;

Marit, Gerald ;

Mathiot, Claire ;

Facon, Thierry ;

Moreau, Philippe ;

Anderson, Kenneth C. ;

Campion, Loic ;

Munshi, Nikhil C. ;

Minvielle, Stephane .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4585-4590

[8] Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 [J].

Barlogie, Bart ;

Anaissie, Elias ;

van Rhee, Frits ;

Haessler, Jeffrey ;

Hollmig, Klaus ;

Pineda-Roman, Mauricio ;

Cottler-Fox, Michele ;

Mohiuddin, Abid ;

Alsayed, Yazan ;

Tricot, Guido ;

Bolejack, Vanessa ;

Zangari, Maurizio ;

Epstein, Joshua ;

Petty, Nathan ;

Steward, Douglas ;

Jenkins, Bonnie ;

Gurley, Jennifer ;

Sullivan, Ellen ;

Crowley, John ;

Shaughnessy, John D. Jr .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (02) :176-185

[9] SERUM BETA-2-MICROGLOBULIN AND SURVIVAL DURATION IN MULTIPLE-MYELOMA - A SIMPLE RELIABLE MARKER FOR STAGING [J].

BATAILLE, R ;

DURIE, BGM ;

GRENIER, J .

BRITISH JOURNAL OF HAEMATOLOGY, 1983, 55 (03) :439-447

[10] High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients [J].

Carrasco, DR ;

Tonon, G ;

Huang, YS ;

Zhang, YY ;

Sinha, R ;

Bin, F ;

Stewart, JP ;

Zhan, FG ;

Khatry, D ;

Protopopova, M ;

Protopopov, A ;

Sukhdeo, K ;

Hanamura, I ;

Stephens, O ;

Barlogie, B ;

Anderson, KC ;

Chin, L ;

Shaughnessy, JD ;

Brennan, C ;

DePinho, RA .

CANCER CELL, 2006, 9 (04) :313-325

← 1 2 3 4 →